Resource Center
Always with a focus on innovation, find resources that share our scientific experts passion and knowledge. Find case studies, info sheets, posters and more.
De-Risking FIH: Integrated Strategies for Rapid Proof-of-Concept
Download79 - 84 of 232 results
Getting it Right Early: The Importance of Biopharmaceutics in Early Drug Development
1 June 2022Why Archiving is a Crucial Part of Any Clinical Trial
17 May 2022Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial
3 May 2022A First-in-Human (FIH) Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses, and Alternative Formulations of R941552 (R552): A selective Receptor Interacting Protein 1 (RIP1) Kinase Inhibitor
24 March 2022A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors
15 March 2022Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [14C]-Belumosudil in Healthy Men: A Phase 1, Open-Label, 2-Part Study
15 March 2022Learn about Quotient Sciences' services
Where integrated CRDMO services bring therapies to life. Whether it's meeting your first-in-human milestone, confidently advancing your program to proof-of-concept, or providing a trusted supply of clinical trial materials or commercial drug product, learn about Quotient Sciences CRDMO offering and how we can support your next drug program.